Redeye comments on Sprint Bioscience’s Q3 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project in late 2022e or H1 2023e. We preliminarily adjust our valuation for the company’s recently announced rights issue and increased cost control measures.